Troy Fabregas, MD
Family Medicine · N Massapequa, NYNPI 1275620999
Payments from drug & device makers
Across 630 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Lilly USA, LLC$867
- Novo Nordisk$815
- AbbVie$778
- Pfizer$698
- plus $6K from 48 others
What the payments were for
- Food & beverage$12,649100%
- Education$250%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$440
- BREZTRI$353
- KYPHON EXPRESS II KYPHOPAK TRAY$175
- OSTEOCOOL RF ABLATION SYSTEM$163
- Repatha$125
- AREXVY$113
- ABRYSVO$105
- FARXIGA$104
How this compares
$12,674 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $97,499 |
| MounjaroTirzepatide | 77 | $84,124 |
| EliquisApixaban | 43 | $46,553 |
| FarxigaDapagliflozin Propanediol | 48 | $44,923 |
| JardianceEmpagliflozin | 31 | $35,368 |
| XareltoRivaroxaban | 17 | $28,025 |
| RexultiBrexpiprazole | 12 | $19,187 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 61 | $18,710 |
| JanuviaSitagliptin Phosphate | 17 | $17,653 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $16,260 |
| Xigduo XrDapaglifloz Propaned/Metformin | 12 | $15,239 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $10,088 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $8,001 |
| SynthroidLevothyroxine Sodium | 72 | $7,713 |
| Repatha SureclickEvolocumab | 14 | $7,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $815 | $97,49975 claims |
| Lilly USA, LLCMounjaro | $867 | $84,12477 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,241 | $52,92461 claims |
| PfizerEliquis | $698 | $46,55343 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $519 | $40,89742 claims |
| GSKArexvy, Trelegy Ellipta, Shingrix | $1,168 | $39,641109 claims |
| Johnson & JohnsonXarelto | $60 | $28,02517 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $71 | $19,18712 claims |
| MerckJanuvia | $403 | $17,65317 claims |
| AbbVieSynthroid | $778 | $7,71372 claims |
| BayerKerendia | $348 | $6,70211 claims |
| Hikma Pharmaceuticals USARyaltris | $32 | $3,24612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in N Massapequa
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.